HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

506.075

-10.940-2.12%

Number of Gainers:9

Number of Losers:21

Number of Flat:3

PE:- -

High:516.490

Open:516.490

Low:500.597

Close:517.015

Volume:149.97M

Turnover:4.87B

Market Cap:324.25B

Float Cap:288.12B

Loading ...

Shinva Medical Secures Class III Medical Device Certification for Single-Use Plasma Surgical Electrode

This Sector Is Experiencing a Major Surge

What We're Really Talking About When We Discuss Innovative Drugs Today

HK Stock Alert | Zai Lab Surges Nearly 7% in Morning Trade as argenx's FcRn-Targeted Drug Succeeds in Phase 3 Trial; Zai Holds Greater China Rights

CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million

Rising Momentum in Innovative Drug Sector: Is the Rally Sustainable?

Antengene Says Phase II Gastric Cancer Study Shows 46.7% ORR for ATG-022 at 1.8 Mg/kg Dose

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

EVEREST MED Posts Strong Interim Results with Revenue Soaring 157% as Nefecon Commercial Launch and Real-World Data Gain Momentum

Everest Medicines H1 Revenue RMB 701.7 Million

THOMSON REUTERS

Everest Medicines FY26 H1 Net Loss Narrows to RMB 5.9 Million; Revenue More than Doubles to RMB 1.15 Billion

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.

CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners

CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million

SinoMab BioScience Sets Sept. 7 Shareholder Vote on Proposed Suzhou Property, Facility Sale

SinoMab BioScience Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management

SinoMab BioScience - Fang Liang Resigns as Executive Director and COO Effective 18 August 2026

THOMSON REUTERS

HBM's Cancer Drug Candidate Gets China Approval

MT Newswires Live

Alphamab's KN026 Combination Therapy for First-Line HER2-Positive Advanced Breast Cancer Receives NMPA Filing Acceptance

Suzhou Basecare Medical Sets Board Meeting to Review Interim Results, Consider Dividend

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK1574/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":506.0749,"timestamp":1787299686774,"preClose":517.0147,"halted":0,"volume":149966252,"delay":0,"changeRate":-0.02116,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.939819,"latestTime":"08-21 16:00:00","open":516.49023,"high":516.49023,"low":500.59692,"amount":4865243342.5,"amplitude":0.030741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.005372,"increases":11,"decrements":20,"flats":2,"marketCap":324245256080,"floatMarketCap":288118014384},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":516.49023,"amplitude":0.030741,"preClose":517.0147,"low":500.59692,"pbRate":"4.109535","latestPrice":506.0749,"volume":149966252,"delay":0,"open":516.49023,"prevYearClose":556.26263,"prevWeekClose":518.327,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":518.327,"twentyDayClose":498.407,"sixtyDayClose":542.586,"secType":"PLATE","market":"HK","turnoverRate":0.005372,"peRate":-81.157718,"marketCap":324245256080,"floatMarketCap":288118014384,"timestamp":1787299686774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":9,"down":21,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1128583126","title":"Shinva Medical Secures Class III Medical Device Certification for Single-Use Plasma Surgical Electrode","url":"https://stock-news.laohu8.com/highlight/detail?id=1128583126","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128583126?lang=en_us&edition=fundamental","pubTime":"2026-08-19 15:48","pubTimestamp":1787125716,"startTime":"0","endTime":"0","summary":"Shinva Medical Instrument Co., Ltd. (600587.SH) announced that its subsidiary, Shinva Surgical Instruments Co., Ltd., has recently received the Medical Device Registration Certificate issued by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","MDEV","BK0251","BK0188","HART","BK1100","PTH","BK1583","RSPH","BK1574","AGNG","09996","600587","159883","LGHT","BK0028","LNGR","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166888801","title":"This Sector Is Experiencing a Major Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1166888801","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166888801?lang=en_us&edition=fundamental","pubTime":"2026-08-19 14:00","pubTimestamp":1787119253,"startTime":"0","endTime":"0","summary":"Since the technology sector cooled off in July, the innovative drug industry chain has taken the lead in market performance. The sector has risen considerably, with leading player Wuxi AppTec...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","MEDX","IBBQ","BK1161","LNGR","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178011845","title":"What We're Really Talking About When We Discuss Innovative Drugs Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1178011845","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178011845?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:20","pubTimestamp":1787109655,"startTime":"0","endTime":"0","summary":"When we talk about innovative drugs, we can't just look at innovative drugs alone. BD out-licensing, the scientific research services and CXO opportunities brought by AI-driven drug development, and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","06978","BK1574","LNGR","BK1161","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195982409","title":"HK Stock Alert | Zai Lab Surges Nearly 7% in Morning Trade as argenx's FcRn-Targeted Drug Succeeds in Phase 3 Trial; Zai Holds Greater China Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=1195982409","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195982409?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:16","pubTimestamp":1787109373,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd (HK: 09688) jumped nearly 7% in early trading on Friday, before settling up 4.61% at HK$20.18, with turnover reaching HK$131 million. The surge comes after immunology company argenx...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","KCAI","BK1574","ZLAB","BK4531","LU2488822045.USD","BK4548","09688","BK4585","BK4588","BK4526","VXUS","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155552295","title":"CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1155552295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155552295?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:20","pubTimestamp":1787106032,"startTime":"0","endTime":"0","summary":"CARSGEN-B (02171) saw its shares rally nearly 5% in Thursday morning trade following the release of its interim results. The stock was up 4.63% at HK$15.38 at the time of writing, with turnover...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1587","BK1574","BK1585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109518315","title":"Rising Momentum in Innovative Drug Sector: Is the Rally Sustainable?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109518315","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109518315?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:11","pubTimestamp":1787105475,"startTime":"0","endTime":"0","summary":"The biopharmaceutical sector has once again captured the spotlight in the financial markets. According to data from Gongmu Paipai.com, between August 3 and August 9, public offering institutions...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1161","BK1574","MEDX","LNGR","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660413291","title":"Antengene Says Phase II Gastric Cancer Study Shows 46.7% ORR for ATG-022 at 1.8 Mg/kg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2660413291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660413291?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:00","pubTimestamp":1787101229,"startTime":"0","endTime":"0","summary":"Antengene says Phase II gastric cancer study shows 46.7% ORR for ATG-022 at 1.8 mg/kg doseAntengene presented updated Phase II CLINCH data for ATG-022, a CLDN18.2 ADC, at the Evercore 2nd China Biotec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL5gksF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK1574","BK1583","EVR","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241822","title":"Press Release: CARsgen Therapeutics Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241822?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:15","pubTimestamp":1787098500,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results.Business Highlights-- Cash and cash equivalents were around RMB1,400 million as of June 30,2026. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,200 million. In light of operational factors, we expect to. -- During H1, 2026, CARsgen has received a total of 110 confirmed orders of. -- Satri-cel receives NMPA approval in June 2026 as world's first and only. CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L. treatment in patients with G/GEJA have been presented at the 2026 ASCO. -- Multiple allogeneic CAR T-cell products are under development based on. the proprietary THANK--u Plus platform. Among them, research results. for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in. the treatment of R/R B--NHL, have been presented at the E","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4612","BK4534","LU0203345920.USD","LU1599440770.SGD","BK4022","PC","LU1032955483.USD","LENZ","000963","02171","CSCO","LU1046421795.USD","LU0950375773.USD","CSCS","LU2328871848.SGD","IE00B1BXHZ80.USD","03160","LU2237443622.USD","LU1674673428.USD","LU0070302665.USD","CSCL","LU0823417653.USD","CAR","TM","IYZ","BK4515","BK0187","LU2506952097.USD","IE00B42XCP33.USD","LU0942090050.USD","BK0209","IE00BVYPNV92.GBP","IE00B3PB1722.GBP","R","BK1574","LU2237443465.HKD","BK4230","LU2417539215.USD","BK1587","LU1221951129.SGD","LU1430594728.SGD","SG9999001424.SGD","AIQ","CIBR","LU0868494617.USD","LU1929549753.HKD","BK4533","BK4560","SG9999001440.SGD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123558217","title":"EVEREST MED Posts Strong Interim Results with Revenue Soaring 157% as Nefecon Commercial Launch and Real-World Data Gain Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1123558217","media":"Stock News","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123558217?lang=en_us&edition=fundamental","pubTime":"2026-08-19 07:14","pubTimestamp":1787094857,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) has announced its interim results for the six months ended June 30, 2026, with revenue reaching RMB 1.148 billion, a substantial 157.29% increase year-over-year.Gross profit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660901934","title":"Everest Medicines H1 Revenue RMB 701.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660901934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660901934?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:54","pubTimestamp":1787093697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nPLX21FCWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490157","title":"Everest Medicines FY26 H1 Net Loss Narrows to RMB 5.9 Million; Revenue More than Doubles to RMB 1.15 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490157","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490157?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:53","pubTimestamp":1787093594,"startTime":"0","endTime":"0","summary":"Everest Medicines FY26 H1 net loss narrows to RMB 5.9 million; revenue more than doubles to RMB 1.15 billionEverest Medicines posted IFRS revenue of RMB 1.15 billion, more than doubled from a year ear","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLb6NYw2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494978","title":"CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494978?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:24","pubTimestamp":1787077458,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-sehk2171-gains-on-ct0596-ind-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4007","BK1161","BK4139","BK1585","LENZ","BK1587","BK4539","IND","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182420401","title":"CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners","url":"https://stock-news.laohu8.com/highlight/detail?id=1182420401","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182420401?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:38","pubTimestamp":1787063895,"startTime":"0","endTime":"0","summary":"CARsgen-B (02171) has released its interim results for 2026, reporting revenue of approximately RMB 61.919 million, a year-on-year increase of 21.5%. The adjusted net loss came in at RMB 31.927...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1574","02171","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544493","title":"CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660544493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:28","pubTimestamp":1787063306,"startTime":"0","endTime":"0","summary":"CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionCARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales vol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbGD37X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","02171","BK0196","BK0175","BK1587","LU2328871848.SGD","BK0132","BK1161","BK0209","BK0188","000963","BK0187","BK1585","BK1574","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460819","title":"SinoMab BioScience Sets Sept. 7 Shareholder Vote on Proposed Suzhou Property, Facility Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460819","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460819?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:05","pubTimestamp":1787058303,"startTime":"0","endTime":"0","summary":"SinoMab BioScience sets Sept. 7 shareholder vote on proposed Suzhou property, facility saleSinoMab BioScience set a 7 September 2026 extraordinary general meeting to vote on its proposed disposal of a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL5MmPCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469023","title":"SinoMab BioScience Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469023?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:45","pubTimestamp":1787049913,"startTime":"0","endTime":"0","summary":"SinoMab BioScience files list of directors, board committee memberships and disclosure-responsible managementSinoMab BioScience listed its board and committee memberships as of Aug. 18, 2026.Executive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL5bw6Cr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660777469","title":"SinoMab BioScience - Fang Liang Resigns as Executive Director and COO Effective 18 August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660777469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660777469?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:43","pubTimestamp":1787049838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469081","title":"HBM's Cancer Drug Candidate Gets China Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469081","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469081?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:43","pubTimestamp":1787049788,"startTime":"0","endTime":"0","summary":"HBM Holdings  said China's National Medical Products Administration approved the investigational new drug application for HBM7004, a bispecific antibody candidate for advanced solid tumors.The approval follows U.S. clearance in May to begin a Phase I trial, allowing the company to advance clinical development in both markets, according to a Tuesday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","HBMX","BK1574","02142","DRMP","MUZ","DRAM","DISK","RAMZ","MUU","DRMY","MUD","MIC","DRAL","RAM","MUYY","MULL","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175281752","title":"Alphamab's KN026 Combination Therapy for First-Line HER2-Positive Advanced Breast Cancer Receives NMPA Filing Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1175281752","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175281752?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:06","pubTimestamp":1787047597,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) has announced that the New Drug Application (NDA) for anitumomab (trade name: Enituo, development code: KN026) in combination with docetaxel injection (albumin-bound) (HB1801) for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466208","title":"Suzhou Basecare Medical Sets Board Meeting to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660466208?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:05","pubTimestamp":1787047548,"startTime":"0","endTime":"0","summary":"Suzhou Basecare Medical sets board meeting to review interim results, consider dividendSuzhou Basecare Medical will hold a board meeting on Aug. 28, 2026.Interim results for the six months ended June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLb0PhCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1222","BK1574","02170"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":7,"totalSize":286,"code":"91000000","status":"200"}]}}